Our data suggest that MYC overexpression compensates for lack of HIF-1 activity in hypoxic SCLC and that targeting regulatory steps in the glutaminolysis and lipogenesis pathways might be novel strategies to eradicate MYC amplified tumor cells. This evidence concerns the gene MYC and neoplasm.